Taysha Gene Therapies (TSHA) Prepaid Assets (2020 - 2026)
Taysha Gene Therapies (TSHA) posted Prepaid Assets of $1.0 million for Q1 2026, down 77.18% sequentially from $4.4 million in Q4 2025, and up 335.78% YoY from $232000.0 in Q1 2025.
Taysha Gene Therapies (TSHA) Prepaid Assets (2020 - 2026) Analysis & Trends
Taysha Gene Therapies has reported Prepaid Assets for 7 years, with the latest figure at $1.0 million in Q1 2026.
- Quarterly Prepaid Assets rose 335.78% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 million (up 335.78% YoY) and the FY2025 annual result came in at $4.4 million, up 67.52% from the prior year.
- Prepaid Assets slipped to $1.0 million in Q1 2026 per TSHA's latest filing, from $4.4 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $4.4 million in Q4 2025 and troughed at $74000.0 in Q3 2022.
- A 5-year average of $930470.6 and a median of $404000.0 in 2023 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2022 and 2025: Prepaid Assets slumped 98.91% in 2022, then surged 1750.91% in 2025.
- Over 5 years, Prepaid Assets stood at $388000.0 in 2022, then slipped by 24.74% to $292000.0 in 2023, then surged by 805.82% to $2.6 million in 2024, then soared by 67.52% to $4.4 million in 2025, then tumbled by 77.18% to $1.0 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $1.0 million, $4.4 million, and $456000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Taysha Gene Therapies | 1.94 Bn | 1.94 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.03 Mn |
| Mar 31, 2026 | 1.01 Mn |
| Dec 31, 2025 | 4.43 Mn |
| Sep 30, 2025 | 456,000.00 |
| Jun 30, 2025 | 3.05 Mn |
| Mar 31, 2025 | 232,000.00 |
| Dec 31, 2024 | 2.65 Mn |
| Sep 30, 2024 | 465,000.00 |
| Jun 30, 2024 | 165,000.00 |
| Mar 31, 2024 | 269,000.00 |
| Dec 31, 2023 | 292,000.00 |
| Sep 30, 2023 | 404,000.00 |
| Jun 30, 2023 | 510,000.00 |
| Mar 31, 2023 | 373,000.00 |
| Dec 31, 2022 | 388,000.00 |
| Sep 30, 2022 | 74,000.00 |
| Jun 30, 2022 | 108,000.00 |
| Mar 31, 2022 | 941,000.00 |
| Dec 31, 2021 | 863,000.00 |
| Sep 30, 2021 | 144,000.00 |